Sean O'donnell

Summary

A dynamic, persuasive and decisive leader, passionate about building strong organizations through a shared strategic vision and a commitment to operational excellence and rapid execution. Credentials include leading transformational strategic initiatives for mature organizations as well as creating rapid growth for emerging companies. A focused and persistent individual with the deliberate intent to win in the marketplace, who builds solid, credible teams and relationships at all levels.

Work History

Work History

President and COO

Consumer Health Services, Inc.
Aug 2003 - Jun 2006

Director, Global Marketing

http://www.Novartis.com
Novartis, AGTop 5 global healthcare products and pharmaceuticals manufacturer in Basel, Switzerland with a leadership position in the development of vaccines and medicines for the treatment of diabetes, cardiovascular, neurological and tropical diseases.Senior Director, Global Marketing, August 2003 to June 2006Charged with providing internal and external leadership in the strategic planning and formation of a new corporate marketing function.This function focused on the creation of external alliances with stakeholder groups to optimize market access and growth potential for pharmaceutical brands under development and through their commercial life-cycle.Established the model framework used to align Novartis brand teams, public affairs, and country organizations to sustain partnerships and to effectively leverage relationships across a franchise portfolio of products in a disease state.

·Launched rapid response program to target and develop top cardiovascular advocates in key EU countries to secure the European regulatory approval that enabled the entrance into the $375 MM market for post-myocardial infarction and heart failure for Novartis’ top selling drug, Diovan.

·Directed comprehensive stakeholder management program to secure commitments of $1.9 Billion in 2005 from major donor countries to assist African nations in purchasing Novartis’ anti-malarial drug, Coartem.

·Led all planning, outreach and implementation of a comprehensive Novartis corporate strategy to establish a leadership position with patient group partners who are key allies for Novartis’ global and country pharmaceutical brand teams.Outreach intitiatives resulted in the first time Novartis secured top 3 ranking among pharma company reputation surveys among Europe’s leading patient group organizations from 2004 to 2006.

·Led cross functional global and country team on the development of a globally supported strategy to optimally position Diovan in two guidance documents developed by the National Institute of Clinical Excellence (NICE) for myocardial infarction and hypertension which significantly shaped European payer and pricing considerations.

·Led the development and execution of a broad-based alliance strategy to optimally position a new hypertensive class in Renin Inhibition with major cardiovascular and renal advocacy organizations.These efforts ensured the external support needed for the regulatory and reimbursement approval in 2007 US and European approval of Novartis’ Tekturna as the first drug in this class valued at $1.5 Billion.